Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births
Abstract Background In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenit...
Main Authors: | Shan-Yan Gao, Qi-Jun Wu, Ce Sun, Tie-Ning Zhang, Zi-Qi Shen, Cai-Xia Liu, Ting-Ting Gong, Xin Xu, Chao Ji, Dong-Hui Huang, Qing Chang, Yu-Hong Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12916-018-1193-5 |
Similar Items
-
Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors
by: Hui Wen, et al.
Published: (2019-01-01) -
Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity
by: Faranak Vahid-Ansari, et al.
Published: (2019-04-01) -
Association between Maternal Birth Weight and Prevalence of Congenital Malformations in Offspring: The Japanese Environment and Children’s Study
by: Hirotaka Hamada, et al.
Published: (2024-02-01) -
Analytical methods for determination of selective serotonin reuptake inhibitor antidepressants
by: Şentürk Zühre, et al.
Published: (2011-06-01) -
Major congenital malformations in offspring of women with chronic diseases—impact of the disease or the treatment?
by: Laila Ülkü Demir, BSc (Med), et al.
Published: (2023-02-01)